In Drosophila lateral glial cell development is initiated by the transcription factor encoded by glial cells missing. glial cells missing activates downstream transcription factors such as repo and pointed which subsequently control terminal glial differentiation. The gene loco has been identi®ed as a potential target gene of pointed and is involved in terminal glial differentiation. It encodes an RGS domain protein expressed speci®cally by the lateral glial cells in the developing embryonic CNS. Here we analyzed the loco promoter and the control of the glial-speci®c transcription pattern. Using promoter±reporter gene fusions we identi®ed a 1.9 kb promoter element capable of directing the almost complete loco gene expression pattern. Sequence analysis suggested the presence of gcm and pointed DNA binding sites. Following in vitro mutagenesis of these sites we demonstrated their relevance in vivo. The expression of loco is initially dependent on gcm. During subsequent stages of embryonic development gcm and pointed appear to activate loco transcription synergistically. In addition, at least two other factors appear to repress loco expression in the ectoderm and in the CNS midline cells. q
Introduction
In the Drosophila central nervous system two major glial classes can be distinguished based on the mechanisms of glial speci®cation and the genes expressed during terminal differentiation, the lateral and the midline glia . The lateral glia comprises more than 90% of the CNS glial cells in the embryonic ventral nerve cord and is derived from the neural ectoderm. Most of these glial cells originate from few identi®ed pluripotent stem cells which generate neuronal as well as glial cells. Only two progenitor cells will exclusively generate glial progeny (Jacobs et al., 1989; Bossing et al., 1996; Schmidt et al., 1997) .
The key regulator of lateral glia development is encoded by the gene glial cells missing (gcm), which acts as a binary switch gene. In gcm mutant embryos no lateral glial cells develop. The presumed glial progenitors are now routed into a neuronal cell fate. Conversely, ubiquitous expression of gcm within the developing nervous system is able to transform almost all neuronal cells into glial-like cells (Hosoya et al., 1995; Jones et al., 1995; Vincent et al., 1996) . gcm function may not even require a neural ground state and can induce at least some glial differentiation markers in the mesoderm when expressed very early during development (Akiyama-Oda et al., 1998; Bernardoni et al., 1998) . Thus, gcm is able to act as a master regulator of glial cell development in the neuroectoderm. However, in the endoderm gcm directs haemocyte development (Bernardoni et al., 1997) .
The expression of gcm, which involves auto-regulation , as well as the subcellular distribution of the gcm transcript in the dividing stem cells is precisely controlled (Akiyama-Oda et al., 1999) . gcm encodes a transcriptional activator with a distinct type of DNA binding domain which binds to an octameric DNA sequence (Akiyama et al., 1996; Schreiber et al., 1997 Schreiber et al., , 1998 . In agreement with the notion that gcm acts as a master regulator of glial cell development, it subsequently activates different genetic programs which control terminal glial development. Three putative gcm target genes encoding different transcription factors have been identi®ed to date.
Within the CNS the gene tramtrack is expressed in all non-neuronal cells. In the lateral glial cells its expression appears to be under the control of gcm and is required to repress the expression of unwanted differentiation genes (Giesen et al., 1997) .
The promoter of the gene repo contains 11 gcm binding sites and repo expression is ef®ciently activated following ectopic expression of gcm (Hosoya et al., 1995; Jones et al., 1995; Akiyama et al., 1996; Vincent et al., 1996) . repo encodes a homeobox type transcriptional regulator which is required for glial differentiation (Campbell et al., 1994; Xiong et al., 1994; Halter et al., 1995) . No target genes of repo have been described to date.
The gene pointed encodes two ETS type transcription factors which in the CNS are speci®cally expressed by glial cells. pointedP1 is expressed only by the lateral glial cells whereas pointedP2 is expressed only by the midline glial cells (Kla Èmbt, 1993) . pointedP1 acts as a constitutively active transcriptional activator. Its activity is required and suf®cient for glial differentiation. In pointed mutants glial differentiation is impaired, whereas ectopic expression of pointed results in an ectopic expression of glial differentiation markers (Klaes et al., 1994) . The DNA binding domain of pointed is well conserved during evolution and pointed can bind to a vertebrate ETS binding site as well as a chick pointed homologue can rescue the pointed mutant phenotype (Albagli et al., 1996) . Although the DNA binding domains of PointedP1 and PointedP2 are identical they appear to activate different non-overlapping sets of target genes.
Thus, gcm appears to control glial development indirectly, via the activation of other transcription factors which subsequently trigger terminal glial differentiation.
loco has been identi®ed as a potential target gene of pointed and is required for glial morphogenesis. The deduced loco protein shows signi®cant sequence similarity to proteins regulating trimeric G-protein signalling (RGS proteins) and is able to directly bind to the Drosophila Gai subunit. Two transcripts are generated from loco gene. Within the CNS, the lococ1 transcript is found exclusively in the lateral glial cells .
Here we have characterized the transcriptional control elements which direct loco gene expression in the lateral CNS glial cells and generated a GAL4 line allowing targeted expression in the lateral glia. We found DNA binding sites for both gcm and pointed within the loco promoter. Deletion analysis as well as ectopic expression experiments indicate that loco expression is initiated by gcm, whereas in later stages loco expression is maintained by a synergistic action of pointed and gcm. Expression in other tissues is repressed by negatively acting transcriptional regulators.
Results

loco is expressed in the lateral glial cells
Using the P[rosy, lacZ] enhancer trap insertion rC56 we had previously identi®ed the Drosophila gene loco as a possible target gene of pointed. Transcription of loco in the embryonic CNS is con®ned to lateral glial cells. In pointed mutant embryos the initiation of loco transcription is not affected, but is reduced in later stages of CNS development (Fig. 1). 
Identi®cation of glial enhancer elements in the loco gene
pointed can activate transcription by direct binding to its target sequences in the genomic DNA (O'Neill et al., 1994; Albagli et al., 1996) . Thus, it seemed reasonable that pointed might regulate loco transcription by binding to a pointed responsive element in the loco promoter/enhancer region. To identify such regulatory elements, we ®rst constructed ®ve loco-promoter-GAL4 or loco-promoterlacZ gene fusions spanning about 12 kb of genomic sequences (Fig. 2) . Following germline transformation, the different constructs were analyzed for their regulatory capacities in vivo, using several independent transformants (see Table 1 for details).
The US1-gal4 fusion contains 7.5 kb of genomic sequences from the 5 H region of the lococ1 transcription unit. It also encompasses the second lococ2 exon. Expression of GAL4 was monitored using a UAS-lacZ transgene. In US1-gal4; UAS-lacZ embryos, ®rst b-galactosidase expression can sporadically be detected at stage 12 in the progeny of the longitudinal glioblast (data not shown). In stage 16 embryos the ventrally located VUM glial cells and subperineurial glial cells express the US1 enhancer. In the dorsal CNS, the segment boundary cell (SBC) expresses the b-galactosidase most prominently. In addition, sporadic activation of the US1 construct is observed in the A and B glial cells as well as rarely in some of the longitudinal glial cells (arrow in Fig. 3B ). Apart from the vector-dependent expression in the salivary glands and the midgut the US1 element is only activated in CNS glial cells.
The 9.6-gal4 fusion contains 2.9 kb of genomic sequences encompassing the entire ®rst lococ1 intron as well as 210 bp of the lococ1-speci®c exon (see Fig. 2 ). In 9.6-gal4; UAS-lacZ embryos, expression of b-galactosidase is found only in old embryos. From stage 16 onwards the VUM and sub-perineurial glial cells can be detected (Fig.  3) . No expression is found in dorsal glial cells.
The Rrk-lacZ fusion contains 1.9 kb of genomic sequences starting 60 bp 5
H to the rC56 P[rosy, lacZ] enhancer trap insertion site and overlaps over 1.2 kb with the genomic sequences cloned in the US1-gal4 construct (Fig.  2) . This element directs b-galactosidase expression in a pattern very similar to lococ1 RNA expression as well as to the b-galactosidase expression conferred by the rC56 enhancer trap. First expression can be detected in stage 11 embryos in lateral cells, which based on their position correspond to the ®rst progeny of the lateral glioblast (Fig. 3D) . During late stage 12 more and more CNS glial cells start to express the Rrk reporter gene (Fig. 3E) . In stage 15 embryos many lateral CNS glial cells can be easily detected using the Rrk reporter and the pattern appears identical to the b-galactosidase expression directed by the rC56 enhancer trap insertion (Figs. 1A and 3F) . Besides expression in the CNS glial cells, the Rrk construct also drives expression in the tracheal system and the salivary glands. These expres-sion domains are not uncovered by the rC56 enhancer trap insertion, however, lococ1 transcript can be detected in the tracheal cells but not in the salivary glands. Expression in the salivary glands is a vector-dependent artefact. The 1.3 1 gal4 construct contains a 2.2 kb fragment overlapping with the 1.9 kb Rrk fragment. It lacks the 5 H 82 bp but extends 500 bp at the 3 H end. Its expression pattern is indistinguishable from Rrk-lacZ.
The 3 H terminal 700 bp of the Rrk-lacZ fusion was used to generate the Nrk-lacZ construct (see Fig. 2 ). This construct is unable to direct any b-galactosidase activity in the embryonic CNS.
pointed in¯uences b -galactosidase expression directed by the Rrk fragment
To test whether the above-identi®ed enhancer elements contain any pointed responsive elements we ®rst assayed their activity in a mutant pointed D 88 (Scholz et al., 1993) background. The pattern of activity driven by the US1 element in wild-type embryos is reminiscent of b-galactosidase activity directed by the enhancer trap insertion rC56 in mutant pointed embryos (Fig.  1 ). This suggests that US1 does not contain a pointed responsive element. In agreement with this notion we did not observe a change in US1 activity in mutant pointed embryos (data not shown).
As observed for the US1 construct the activity of the 9.6 element is not modulated by pointed function and thus does not appear to contain a pointed responsive element either (data not shown).
However, Rrk-mediated b-galactosidase expression is clearly altered in mutant pointed embryos (Fig. 4A,B) . Expression in the A and B glial cells is retained but expression in the longitudinal glial cells is reduced. Interestingly, the in¯uence of pointed on the expression of the Rrk enhancer declines towards the most caudal neuromeres. A similar observation had been made for the rC56 insertion (Fig. 1 ).
glial cells missing is required for the activity of the Rrk enhancer
In the embryonic CNS the fate of the lateral glial cells is speci®ed by the activity of the gene glial cells missing, which acts as a master gene of glial development. In agreement with the notion that the different enhancers of the loco gene activate transcription only in glial cells, no glial bgalactosidase expression was observed in gcm mutant embryos (Fig. 4C,D) .
Besides gcm and pointed the transcription factor repo is expressed in the lateral glial cells. To test a possible relationship of loco expression and repo function we analyzed the Rrk expression pattern in a homozygous mutant repo EX84 background (Halter et al., 1995) . No alterations in the pattern of b-galactosidase expression were detected, indicating that repo is not required for the establishment or maintenance of loco expression.
pointed and gcm synergistically activate the Rrk enhancer
To further analyze the role of pointed and gcm during the activation of the Rrk enhancer we ectopically expressed UAS-pointedP1 or UAS-gcm transgenes using the GAL4 technique (Brand and Perrimon, 1993) . In stage 10 embryos the driver line rho-GAL4 directs UAS-mediated gene expression in all midline cells, the neuroectodermal cells anking the midline as well as mesodermal cells (Fig.  5A ). Following expression of pointedP1 in this pattern, few cells¯anking the midline start to express the Rrk reporter construct, even before endogenous expression of the Rrk enhancer can be detected (Fig. 5B,C) .
Following ectopic expression of gcm in the rho-gal4 pattern, we obtained a qualitatively similar result as following pointedP1 expression (Fig. 5D ). These ®ndings indicate that the Rrk fragment contains both pointed and gcm responsive elements. No expression of the Rrk construct was observed in cells of the CNS midline or in the mesodermal cells.
From the above-mentioned experiments both pointed and gcm appear to be required for the establishment of the Rrk enhancer activity. However, neither transcription factor alone is able to activate the Rrk reporter gene in a very ef®cient manner. We thus coexpressed gcm and pointed in embryos carrying the Rrk construct, again using the rhogal4 line. In these experiments we observed a pronounced increase in the activation of the Rrk enhancer in ectodermal domains which do not respond to either gcm or pointedP1 alone (Fig. 5E ), indicating that pointed and gcm synergistically activate loco expression.
It is interesting to note that not all embryonic cells appeared equally competent to activate the Rrk construct in response to ectopic gcm and pointed. Although the CNS midline cells as well as mesodermal cells express high levels of gcm and of pointed they never express the 
a GBS1±3, possible gcm binding sites 1±3; EBS, possible ETS binding site.
Rrk-lacZ reporter gene. Thus, either speci®c cofactors of gcm and pointed are missing in these cells or speci®c transcriptional repressors are expressed within the midline which block the expression of lateral glial-speci®c gene expression.
Activity of the Rrk enhancer is inhibited in the ectoderm
One such transcriptional repressor might be the abrupt protein. abrupt is a BTB-Zinc-®nger transcription factor expressed in high levels in the midline as well as in the epidermal cells (Hu et al., 1995) . As with other BTB-Zinc ®nger proteins such as tramtrack (Brown et al., 1991; Brown and Wu, 1993; Giesen et al., 1997) , abrupt is thought to act as a transcriptional repressor (Hu et al., 1995) . In agreement with this notion we observed an expansion of Rrk-mediated b-galactosidase expression in mutant abrupt embryos (Fig.   5F ,G). Ectopic Rrk activity is detected in segmental epidermal stripes in the apodemata. The cells, which can be easily identi®ed by their speci®c position and shape, appear to correspond to the gcm positive epidermal cells (Fig. 5H) . Similarly, loco RNA expression is found in the apodemes of mutant abrupt embryos, indicating that abrupt is required for repression of gcm-dependent loco expression in the ectoderm.
In contrast no Rrk-mediated expression was observed in the CNS midline of mutant abrupt embryos. Furthermore, coexpression of gcm and pointed in mutant abrupt embryos did also not lead to an activation of the Rrk enhancer in the CNS midline cells (data not shown). Thus, abrupt might act as a transcriptional repressor preventing the function of gcm as an activator of glial development in the ectoderm. In the CNS midline abrupt does not appear to exert such a function and a similar acting protein remains to be identi®ed. 
Sequence analysis of the Rrk element
The above experiments suggested the presence of DNA binding sites for pointed, gcm and abrupt within the Rrk promoter element. DNA binding consensus motifs have been described for the transcriptional regulators gcm and pointed (Wasylyk et al., 1993; Akiyama et al., 1996; Schreiber et al., 1997) .
Since the DNA binding domains of Drosophila pointed and mammalian ets1 are 96% identical (Kla Èmbt, 1993) , both factors likely bind to the same DNA sequence (Albagli et al., 1996) . One ets binding site (EBS) was found at position 1618±1630. The sequence is conserved in 7 of 11 positions compared to the ets1 site in the long terminal repeat of HTLV (Wasylyk et al., 1990) (Fig. 6) .
gcm binds to the consensus motif A T G/A C G G G C/T. Three possible gcm binding sites (GBS) were found. Two of them, GBS1 and GBS2, are located 5 H to the NotI restriction site and are thus contained within the US1 fragment. The US1 element confers only pnt-independent glial enhancer activity. GBS1 ®ts the published DNA binding consensus sequence, whereas GBS2 contains one mismatch at position 8 (adenin instead of pyrimidin; see Fig. 6 ). The third GBS as well as the ETS binding site are located 3 H to the NotI restriction site and are thus included in the Nrk construct, which is unable to drive b-galactosidase expression in wildtype embryos. GBS3 ®ts the published consensus gcm binding sequence and as GBS1 is found in inverse orientation.
No DNA binding motives were found for repo and single minded.
Functional analyses of the different deduced binding sites
To determine the relevance of these potential transcription factor binding sites we mutagenized all individual sites and generated several constructs carrying different combinations of mutant sites (see Table 1 for details). Following germline transformation, b-galactosidase expression was in each case monitored in several independent transformants to eliminate possible chromosomal position effects.
The three deduced gcm binding sites appear to contribute differentially to the activity of the Rrk enhancer. Deletion of GBS1 is suf®cient to eliminate almost all glial enhancer activity of the Rrk element (Fig. 7A) . Deletion of GBS2 or GBS3 leads to a reduction in the early expression of the Rrk enhancer but from stage 14 onwards b-galactosidase expression can be detected in the longitudinal glial cells. Deletion of GBS2 yields less pronounced effects compared to deletion of GBS3 (Fig. 7B,C) . A construct carrying a deletion of both GBS1 and GBS2 drives b-galactosidase expression as observed when only GBS1 is disrupted (data not shown). Deletion of GBS2 and GBS3 results in a very strong reduction in glial b-galactosidase expression (Fig.  7D) . Deletion of GBS1 and GBS3 is suf®cient to disrupt all glial-speci®c expression of the reporter gene (Fig. 7E) .
These data suggest that loco expression is directly controlled by binding of gcm. However, although GBS1 appears crucially important to direct Rrk enhancer activity in glial cells, it is apparently not suf®cient to direct expression in the US1 reporter construct which lacks the potential pointed binding site as well as GBS3.
The Nrk fragment does not contain the GBS1 and GBS2 sites and does not confer any glial reporter gene activity. In contrast, the Rrk fragment lacking GBS1 and GBS2 does show some glial activity. Thus, we have to conclude that 5 H of the NotI site additional sequence elements exist in the Rrk fragment, which are required for glial transcription.
Deletion of the pointed binding site did not affect early expression directed by the Rrk enhancer and reporter gene expression can be detected in the progeny of the glioblast in stage 12 embryos (Fig. 7F) . At stage 15 reduced levels of b-galactosidase expression were detected in the longitudinal glial cells and became hardly detectable in stage 16 embryos (Fig. 7G,H) . The pattern resembles the Rrk enhancer activity in a mutant pointed background. Thus, pointed and gcm both appear to directly regulate loco gene expression. gcm is required for the initiation of loco expression in early development. In later stages pointed activity is needed to upregulate loco expression, in a process that requires gcm.
Discussion
The initiation of glial gene expression is controlled by the master regulatory gene glial cells missing (gcm) (Hosoya et al., 1995; Jones et al., 1995; Vincent et al., 1996) . Although gcm shows robust positive auto-regulation, gcm expression disappears by mid-embryogenesis . Thus, terminal glial differentiation likely involves additional later acting transcription factors such as pointed and repo. These transcription factors then control the expression of genes required for terminal glial differentiation. Here we have analyzed the transcriptional regulation of loco which is required for late glial differentiation .
Regulation of loco expression
Two alternative modes as to how loco transcription might be regulated are depicted in Fig. 8 . In the simple model, a linear array of transcriptional regulators results in the correct expression of loco. gcm acts on top of this cascade and activates pointed, which in turn leads to glial-speci®c loco expression (Fig. 8A) . Alternatively, loco gene activation might be biphasic (Fig. 8B) . Initially gcm concomitantly activates both loco and pointed. In a second phase, gcm and pointed act synergistically on the loco promoter to mediate high levels of glial-speci®c loco expression. Our data favour the latter model. 
Synergistic interaction of gcm and pointed
The Rrk promoter element is capable of directing expression of the lacZ reporter in the complete loco expression domain. The Rrk fragment itself appears to contain more than one crucial regulatory element. The US1 construct, which harbours two gcm binding sites located in the 5 H part of the Rrk fragment, directs glial expression resembling the expression of loco in a pointed mutant background. The 3 H sequences of the Rrk fragment are found in the Nrk fragment. This promoter fragment, which harbours one gcm and one pointed binding site, is not able to confer any glial expression. Only the complete Rrk fragment is able to direct the entire loco transcriptional pro®le pointing to synergistic effects of proteins binding to the 3 H and 5 H portions of the Rrk element. This notion is supported by the observation that pointed cannot activate the Rrk element when both GBS1 and GBS3 are deleted.
Ectopic expression of either gcm or pointed alone within the neuroectoderm leads to sporadic activation of the Rrk enhancer suggesting the presence of both gcm and pointed responsive elements. Coexpression of gcm and pointed in the rhomboid expression pattern shows two interesting results. First, it is evident that cells within neuroectoderm activate the Rrk reporter gene very strongly showing that the two transcription factors act synergistically. Second, it is important to note that although comparably high levels of gcm and pointed are found in the CNS midline and the mesodermal cells, they never activate the Rrk reporter. Coexpression of gcm and pointed can also direct expression of the Nrk reporter. Within the Nrk fragment only one gcm and one pointed binding site are found 370 bp apart.
gcm is the master regulatory gene controlling lateral glial cell development (Hosoya et al., 1995; Jones et al., 1995; Vincent et al., 1996) . The gene pointed is not expressed in mutant gcm embryos (Giesen et al., 1997) suggesting that pointed expression depends on gcm. However, only coexpression of pointed and gcm leads to an ef®cient activation of the Rrk enhancer indicating that gcm can not ef®ciently activate pointed transcription in the neuroectoderm.
Despite the fact that pointedP1 is thought to act as a transcriptional activator it appears that cofactors such as gcm are required to allow full activation. This parallels results obtained in vertebrate systems, where binding of cofactors is discussed as a mechanism to relieve auto-inhibition of ETS proteins (Wasylyk et al., 1992; Batchelor et al., 1998) . pointed is expressed in many tissues during development and activates very different sets of genes (e.g. depending on the cells in which pointedP1 is expressed it activates tracheal, epidermal, neuronal or glial development). Interaction with different tissue-speci®c coactivators might thus be an important step in selecting the appropriate downstream target genes. Direct coactivation of glial target genes by both gcm and pointedP1 is possibly not con®ned to loco; the analysis of a second pointed-dependent enhancer element revealed the presence of putative binding sites for both gcm and pointed (S.G. and C.K., unpublished data). The synergistic activation of loco by gcm and pointed could suggest that pointed might be able to recruit or stabilize gcm at the regulatory regions of terminal differentiation genes. This would lead to an increased expression of the respective genes but concomitantly could also disrupt the positive auto-regulatory feedback loop found for the gcm gene. This would provide a possible mechanism as to how the positive auto-regulation of gcm is terminated. How loco expression is maintained in vivo remains to be addressed.
Regulation of slit expression
A very similar mode of transcriptional regulation comprising direct and indirect activation steps has been proposed for the slit gene. slit is expressed by the midline glial cells and encodes a secreted protein that acts as a conserved repulsive guidance signal (Rothberg et al., 1990; Battye et al., 1999; Brose et al., 1999; Kidd et al., 1999; Wu et al., 1999) . Initial slit expression is regulated by the master gene of midline development encoded by single minded (sim) Thomas et al., 1988) . sim encodes a bHLH/PAS domain protein which together with the ARNT type transcription factor tango speci®es CNS midline cell fate (Nambu et al., 1991; Sonnenfeld et al., 1997) . In sim mutant embryos all midline cells degenerate and conversely ectopic expression of sim in the neuroectoderm directs these cells into a midline cell fate (Nambu et al., 1991; Sonnenfeld and Jacobs, 1994; Menne et al., 1997) . Analogous to gcm, sim is capable of positively in¯uencing its own transcription (Nambu et al., 1991; Muralidhar et al., 1993) . sim activates early slit expression in the midline glia by directly binding to several distinct enhancer elements of the slit promoter (Wharton and Crews, 1993) . Concomitantly, single minded activates the expression of the ventral veinless/drifter (Anderson et al., 1995; de Celis et al., 1995; Crews, 1998) which also shows positive auto-regulation (Certel et al., 1996) . Presumably sim activates the transcription of Dichaete/®shhook as well (Nambu and Nambu, 1996; Russell et al., 1996) . Dichaete and ventral veinless are both expressed in the midline glial cells. Dichaete encodes a SOX domain transcription factor and ventral veinless encodes a POU domain transcription factor which can interact in vitro. In Dichaete or vvl single mutants expression of slit is not altered, however, in embryos mutant for both these genes almost no slit expression can be detected (SanchezSoriano and Russell, 1998) . Presumably expression is regulated by a Dichaete/ventral veinless complex (Ma et al., 1998; Sanchez-Soriano and Russell, 1998) . Thus, sim apparently regulates slit expression both directly and indirectly via vvl/D.
3.4. What determines the distinction between pointedP1 and pointedP2 target genes?
Terminal differentiation of glial cells is controlled by pointed. Two different isoforms are generated from the pointed locus, pointedP1 and pointedP2. They share the DNA binding domain and during embryonic CNS development they are expressed in the lateral glia (pointedP1) or the midline glia (pointedP2). Despite the common DNA binding activity, the two factors activate non-overlapping sets of target genes in the different glial cell types.
The mechanism by which the selection of glial pointedP1 and pointedP2 target genes occurs appears to be complex. A simple model would be to postulate that speci®c ± still unidenti®ed ± cofactors are expressed either in the neuroectoderm or the CNS midline cells. However, in the midline, pointedP2 function can be substituted by pointedP1 (Scholz et al., 1997) . This might be explained by postulating that pointedP1 is able to interact with a pointedP2 coactivator. Besides gcm additional factors appear to be required to specify pointedP1 target genes, as the coexpression of pointedP1 and gcm in the CNS midline is not suf®cient to evoke any Rrk reporter gene expression.
Alternatively, the discrimination of pointedP1 and pointedP2 target genes might be mediated by transcriptional repressors. Two such proteins are known to be expressed in the CNS midline: single minded and abrupt (Hu et al., 1995; Mellerick and Nirenberg, 1995) . No potential single minded binding sites were found in the Rrk construct. One potential abrupt binding site (Kalionis and O'Farrell, 1993; Hu et al., 1995) 
(C T T A A T T A A at position 1537±1547
of the Rrk fragment) was predicted by DNA sequence analysis. However, disruption of this site did not alter the reporter gene expression directed by the Rrk fragment in vivo (data not shown).
Thus, if abrupt directly acts on the lococ1 promoter, it must bind to a different site in the Rrk fragment. abrupt apparently represses Rrk-mediated expression (and possibly expression of other gcm-dependent genes) only in the apodemata, which might explain the muscle attachment defects observed in abrupt mutant embryos (Hu et al., 1995) . In the CNS midline, however, the function of abrupt is not required for the repression of loco. Thus, additional experiments are required to determine which mechanisms are used in vivo to discriminate between lateral and midline glial gene expression.
Materials and methods
Fly work
All¯y work was performed according to common practice. For germline transformations, DNA constructs were injected at a concentration of 0.3 mg/ml in the presence of 0.1 mg/ml helper DNA (pUChsD2-3, Laski et al., 1986) into preblastoderm white 1118 embryos.
Immunohistochemistry
Immunohistochemistry was performed as described previously . Reporter gene expression patterns were analyzed in at least two independent transformant lines per construct.
DNA work
All DNA manipulations were carried out using standard procedures. Sequences were obtained from an ABIPRISM 310 Genetic Analyser (Applied Biosystems) using the dRhodamine Dyedeoxy Terminator Kit (Perkin Elmer). Sequence analysis was performed with the Lasergene DNASTAR software package.
Cloning of reporter gene constructs
The US1-gal4 construct was obtained by cloning a 7.5 kb SpeI-NotI fragment from l109g1 into p221-4 (kindly provided by A. Bachmann and E. Knust) opened with XbaI and NotI. For 9.6-gal4, the 2.9 kb EcoRI fragment containing most of ExonI-1 and IntronI-1 (see was inserted into EcoRI-opened p221-4. RrklacZ was generated by cloning the 1.9 kb BamHI-XhoI fragment from prk.3 into pCAB70 cut with BglII and XhoI (Bachmann and Knust, 1998) . Cloning of the 0.7 kb NotIEcoRI fragment from prk.3 into pCAB70 yielded Nrk-lacZ. 1.3 1 gal4 was generated by cloning the 2.2 kb EcoRI fragment from p1.3 into p221-4.
Binding-site knockouts
In vitro mutagenesis was performed using the ExSite PCR-based Site-directed Mutagenesis Kit (Stratagene) according to the manufacturer's instructions, using prK.3 as a template.
The following primers were used: DG1-3 (TCT AGA TAT CTT CCA TAA AAT TAA CGC AA) and DG1-5 (CAT ATG CGT TCT GTT CAG AAA) for GBS1; DG2-3 (TCT AGA AAT TAT AGT TCC CTA TAT TTT TTT G) and DG2-5 (TTT ACG CAC TTC GCA CTG GT) for GBS2; DG3-3 (TCT AGA TCC CAG TTG CCT TTG CTT GGC A) and DG3-5 (GGC CGC TGC TTG TTG TTG TGC) for GBS3; DA3 (GGTACC GGC CAA AAG GCT GAA AAA GCC A), and Cw1590r (ATC GAT GCA CGC CCC AAG TGA CGC) and Cw1606f (ATC GAT GAG AGC GAG CAC ACC CAC AAC A) for the putative pointedP1 binding site. The restriction sites added at the 5 H ends of the oligos allowed unambiguous identi®cation of mutant clones. In addition the deletions of the target sequences were veri®ed by sequencing the mutated region. Clones containing two or three GBS deletions were obtained by recombining appropriate restriction fragments from the singly mutant plasmids. All mutated Rrk fragments were ®nally cloned into pCAB70 as described above and recon®rmed by sequencing.
